A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair
Brief Summary
Background: Sedation is often needed for young children undergoing minor procedures in the emergency department (ED). Oral midazolam is one of the most commonly used regimens for children undergoing laceration repair but its sedative efficacy was shown to be suboptimal. In a few studies oral ketamine has been used successfully for procedural sedation as well. The efficacy of using a combination of oral midazolam and oral ketamine for procedural sedation has been studied only for invasive procedures in children with malignancies. No randomized controedll studies were performed using this sedative combination in children requiring laceration repair. Objectives: To determine the efficacy of adding oral ketamine to oral midazolam for procedural sedation in children requiring laceration repair compares to oral midazolam plus placebo. Design: A randomized, double blind, placebo-controlled study. Setting: Pediatric Emergency Department. Participants: Children 1 to 10 years with laceration requiring sedation. Interventions: Eligible patients will be randomly assigned to one of two treatment groups: oral midazolam plus oral placebo group and oral midazolam plus oral ketamine group. Both groups will be given the same volume of medications. Midazolam will be given orally in a dose of 0.5 mg/kg (max.-15 mg) with placebo or 0.5 mg/kg (max.- 15 mg) with oral ketamine in a dose of 5 mg/kg. The medical staff will be blinded to the treatment given. Patient monitoring will be conducted according to the American Academy of Pediatrics (APP) and the Israeli health ministry guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Main outcome measures: Pain score: Visual Analog Score (VAS) - by parent. Data analysis: Descriptive statistics will be used to describe the study population. Data will be analyzed using t- tests for continuous data and Fisher exact test for categorical data.
Key words: sedation, children, ketamine, midazolam, emergency department.
Intervention / Treatment
-
Ketamine (DRUG)5mg/kg as oral suspension
-
Normal saline (DRUG)Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Condition or Disease
- Lacertaions
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Unknown status |
Study results: | No Results Available |
Age: | 1 Year to 10 Years |
Enrollment: | 60 (ESTIMATED) |
Funded by: | Other |
Allocation: | Randomized |
Primary Purpose: | Treatment |
MaskingQUADRUPLE:
|
Clinical Trial Dates
Start date: | Jul 01, 2011 | |
---|---|---|
Primary Completion: | Mar 01, 2012 | ESTIMATED |
Completion Date: | Jul 01, 2012 | ESTIMATED |
Study First Posted: | Nov 11, 2011 | ESTIMATED |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | Nov 09, 2011 |
Sponsors / Collaborators
Lead Sponsor:
Assaf-Harofeh Medical Center
Responsible Party:
N/A
Participant Groups
-
Oral Ketamine in addition to oral midazolam
-
Normal saline (placebo) in addition to oral midazolam
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 1 |
Maximum Age: | 10 |
Age Groups: | Child |
Healthy Volunteers: | Yes |
Inclusion Criteria:
* Age: 1 years - 10 years
* Any child with laceration requiring sedation
Exclusion Criteria:
* Major trauma
* Closed head injury associated with loss of consciousness
* Abnormal neurologic examination in a previously normal child
* Significant developmental delay or baseline neurological deficit
* A patient with seizures
* Elevated intra-cranial pressure
* Hypersensitivity to midazolam or ketamine
* Hypertension
* Hyperthyroidism or a patient receiving thyroid replacement
* alcohol intoxication or a history of alcohol abuse
* Acute or chronic respiratory, cardiac, renal or hepatic abnormalities
* Glaucoma
* Known psychiatric disease
* ASA score of more than 2
* Informed consent cannot be obtained from legal guardian
* Age: 1 years - 10 years
* Any child with laceration requiring sedation
Exclusion Criteria:
* Major trauma
* Closed head injury associated with loss of consciousness
* Abnormal neurologic examination in a previously normal child
* Significant developmental delay or baseline neurological deficit
* A patient with seizures
* Elevated intra-cranial pressure
* Hypersensitivity to midazolam or ketamine
* Hypertension
* Hyperthyroidism or a patient receiving thyroid replacement
* alcohol intoxication or a history of alcohol abuse
* Acute or chronic respiratory, cardiac, renal or hepatic abnormalities
* Glaucoma
* Known psychiatric disease
* ASA score of more than 2
* Informed consent cannot be obtained from legal guardian
Primary Outcomes
-
Pain score: Visual analog score (VAS)- by parent participants will be followed for the duration of hospital stay, an expected average of 3 hours
Secondary Outcomes
-
Pain score: Visual analog score (VAS)- by a physician while in the ED for about 3 hours
More Details
NCT Number: | NCT01470157 |
---|---|
Other IDs: | 22/11 |
Study URL: | https://clinicaltrials.gov/study/NCT01470157 |
Last updated: Sep 29, 2023